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Abstract: Shiga toxin 1 (Stx1), produced by pathogenic Escherichia coli, targets a 
restricted subset of human cells, which possess the receptor globotriaosylceramide 
(Gb3Cer/CD77), causing hemolytic uremic syndrome. In spite of the high toxicity, Stx1 
has been proposed in the treatment of Gb3Cer/CD77-expressing lymphoma. Here, we 
demonstrate in a Burkitt lymphoma cell model expressing this receptor, namely Raji cells, 
that Stx1, at quasi-non-toxic concentrations (0.05–0.1 pM), inhibits the repair of 
mafosfamide-induced DNA alkylating lesions, synergistically potentiating the cytotoxic 
activity of the anticancer drug. Conversely, human promyelocytic leukemia cells HL-60, 
which do not express Gb3Cer/CD77, were spared by the toxin as previously demonstrated 
for CD34+ human progenitor cells, and hence, in this cancer model, no additive nor 
synergistic effects were observed with the combined Stx1/mafosfamide treatment. Our 
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findings suggest that Stx1 could be used to improve the mafosfamide-mediated purging of 
Gb3Cer/CD77+ tumor cells before autologous bone marrow transplantation. 
Keywords: Shiga toxin 1; Gb3Cer/CD77-expressing lymphomas; mafosfamide; DNA 
repair; autologous bone marrow transplantation 
 
1. Introduction 
Shiga toxin 1 (Stx1), produced by some pathogenic Escherichia coli strains [1], damages cellular 
nucleic acids by removing a specific adenine from 28S rRNA in ribosomes [2] and multiple adenines 
from DNA in vitro [3]. This leads to inhibition of protein synthesis in the cytoplasm and formation of 
apurinic sites in the nucleus of target eukaryotic cells [4,5]. At quasi-non-toxic concentrations, Stx1 
also blocks the DNA repair of lesions induced by oxidizing and alkylating agents [6]. This effect is 
unrelated either to inhibition of protein synthesis or to depletion of cellular antioxidant defenses and is 
likely to derive from direct interactions with cellular DNA repair machinery [6]. It should be noted 
that, although in these conditions Stx1 reaches the nucleoplasm and the cytoplasm, DNA was 
undamaged and translation little affected [6]. Thus, the spectrum of toxin actions in sensitive cells 
depends on the concentration of the toxin, being considered a DNA repair inhibitor at low dosage.  
Stx1 targets normal [1,7] and cancer [8,9] human cells expressing globotriaosylceramide 
(Gb3Cer/CD77) on their membrane. In hematological cells, Gb3Cer/CD77 is expressed on the surface 
of a narrow range of committed B lymphocytes present in germinal centers, as well as on the 
associated B-cell lymphomas, such as Burkitt lymphoma [10]. In particular, Gb3Cer/CD77 was found 
to be highly accumulated in lymphoma cell lines [11]. This receptor has also been detected in biopsies 
from 70% of patients with follicular lymphoma and 30%–40% of patients with small lymphocytic 
lymphoma [10,11].  
About 50% of patients with low-grade or intermediate-grade non-Hodgkin lymphoma are treated 
with high-dose chemotherapy followed by autologous bone marrow transplantation. In this context, a 
widely used drug is mafosfamide, an alkylating agent forming DNA cross-links and DNA strand 
breaks, inhibiting DNA synthesis and triggering apoptosis in target cells [12]. Mafosfamide is a stable 
salt of 4-OH-cyclophosphamide that does not require metabolic activation. This renders the drug 
suitable for the elimination of cancer cells before autologous bone marrow transplantation [12]. Stx1 
has also been proposed as a selective purging agent against Gb3Cer/CD77+ cells in this context, as this 
toxin has shown no toxicity against CD34+ human progenitor cells, which do not express 
Gb3Cer/CD77 [10]. However, the safety of Stx1 as a purging agent in an ex vivo setting has been 
questioned, since Gb3Cer/CD77 is also expressed by cerebral, intestinal and renal endothelia and by 
renal cells in humans [1]. The consequence of the damaging effects of Stx1 on these cells is the 
development of hemorrhagic colitis and of the life-threatening sequela hemolytic uremic syndrome, 
the main cause of acute renal failure in early childhood [13,14]. Although residual toxin in the purged 
marrow could be removed by extensive washing or by neutralizing antibodies [10], the risk of toxicity 
is still fairly high since Stx1 acts on these cells at picomolar concentrations. We investigated here the 
effects of lower concentrations of Stx1 on a Burkitt lymphoma cell line, namely Raji, which expresses 
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Gb3Cer/CD77 [15], and on the human myeloid leukemia cells HL-60, which do not harbor even trace 
amounts of the receptor on their membrane [16]. DNA repair of lesions induced by the alkylating 
agent mafosfamide in Raji cells was inhibited by Stx1, resulting in synergistic cooperation between the 
bacterial toxin and the purging agent in the elimination of Raji cancer cells. Conversely, DNA repair 
and protein synthesis were unaffected in HL-60 cells treated with Stx1, which did not elicit any toxic 
effect on these cells either alone or in combination with mafosfamide. 
2. Results 
The time course of the inhibition of protein synthesis in Raji cells incubated with 10 pM Stx1 is 
shown in Figure 1. Raji cells were very sensitive to the damaging effects induced by Stx1, which was 
internalized within 90 min, as indicated by the almost total inhibition of translation caused by the 
toxin-induced ribosomal lesions. 
Figure 1. Time course of inhibition of protein synthesis in Raji cells treated with 10 pM 
Shiga toxin 1 (Stx1). The SD values (n = 3) of single points are indicated. 
 
Figure 2. Effect of Stx1 on protein synthesis in Raji cells or HL-60 cells. Cells (1 × 106) 
were either untreated or treated with Stx1, as described in the Figure. Post-incubation was 
performed after a single wash followed by resuspension in 1.5 mL complete medium. At 
the end of post-incubation, the rate of protein synthesis was measured, as described in 
Experimental section. The [3H]leucine incorporated by untreated Raji cells or untreated 
HL-60 cells was 16,358 ± 3503 dpm (n = 3) or 20703 ± 2691 dpm (n = 3), respectively. 
Data are expressed as percent of translation with respect to controls; the SD values (n = 3) 
of single points are indicated. 
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Figure 3. Inhibition of DNA repair induced by Stx1 and 3-aminobenzamide (3AB) of 
mafosfamide-dependent alkylative lesions. Raji cells were either untreated or treated with 
0.1 pM Stx1 (A) or 5 mM 3AB (B), as described in the upper panels. HL-60 cells were 
either untreated or treated with 0.1 pM Stx1 (C) or 5 mM 3AB (D), as described in the 
upper panels. After 5 min centrifugation at 200 × g and washing, pelleted cells resuspended 
in 1.5 mL complete medium were either untreated or treated with 5 μg/mL mafosfamide 
(Ma) and washed. Then, cells were seeded in 1.5 mL complete medium in 3.5 cm diameter 
dishes for 48 h at 37 °C. In the case of the diffusible 3AB, washings were performed in the 
presence of the DNA repair inhibitor. After mafosfamide treatment, cells were allowed to 
repair nuclear DNA lesions in drug-free culture medium. The level of residual DNA strand 
breakage was determined with FHA at increasing time intervals (up to 6 h). Data are 
expressed as relative nuclear spreading factor (RNSF) (see Experimental section) and are 
the mean ± SEM from at least four separate experiments. * p < 0.001 as compared to cells 
exposed to mafosfamide alone and allowed to repair for the indicated times (t-test). 
 
Incubation of Raji cells for 90 min at 37 °C with lower concentrations of Stx1 (0.02–1 pM) 
followed by 48 h post-incubation in toxin-free medium caused a dose-dependent inhibition of 
translation (Figure 2). Under the same conditions, Stx1, tested at 10-fold higher concentration, did not 
elicit any effect on translation in HL-60 cells (Figure 2). In Raji cells, lowering the toxin concentration 
at 0.1 pM, induced poor toxic effects, as protein synthesis was about 25% impaired (Figure 2) and no 
damaging effects on DNA were detected by the fast halo assay (FHA) [17] (not shown). This sensitive 
assay has been employed to demonstrate for the first time the damaging effects of Shiga toxins on 
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nuclear DNA in human endothelial cells treated with higher toxin concentrations [4,5]. When Raji 
cells or HL-60 cells were challenged with the alkylating drug mafosfamide (5 μg/mL) in the presence 
of Stx1 at the same low-toxic 0.1 pM concentration (experimental setting in Figure 3), the repair of 
mafosfamide-induced DNA lesions, assessed by FHA, was completely inhibited in Raji cells  
(Figure 3A) and fully efficient in HL-60 cells (Figure 3C). 
A similar DNA repair impairment was observed in Raji cells and HL-60 cells by substituting  
3-aminobenzamide (3AB, 5 mM) for Stx1 (Figure 3B,D). 3AB is a well known inhibitor of the 
enzyme poly(ADP-ribose)polymerase (PARP), which is involved in DNA repair of alkylative lesions. 
In this case, the experimental setting was modified to allow the presence of the diffusible inhibitor 
during the repair time (see right panel, Figure 3). The extents of DNA repair inhibition over time 
obtained in Raji cells with Stx1 and 3AB were comparable (Figure 3).  
With the same experimental settings (Figure 3), we also evaluated Raji cell viability, measured with 
the trypan blue dye exclusion test, after treatment with different concentrations of mafosfamide  
(1–10 μg/mL) in the absence and in the presence of Stx1 (0.05 pM) or 3AB (5 mM). To minimize the 
toxic effects on cells, in these experiments, the concentration of Stx1 was halved with respect to that 
used to completely inhibit DNA repair. As shown in the representative experiments in Figure 4A and 
4B, mafosfamide strongly reduced the number of live Raji cells in a dose-dependent fashion, while 
Stx1 or 3AB, at the tested concentrations, did not elicit any effect on cell proliferation and viability. 
However, the number of viable cells was significantly lower in the presence of the combined treatment 
Stx1/mafosfamide (Figure 4A) to an extent comparable to that obtained with the reference DNA repair 
inhibitor 3AB (Figure 4B). It is worth noting that 3AB is a diffusible inhibitor that enters cells in a 
non-specific way, while Stx1, due to its receptor-mediated cell-type specific uptake, selectively 
hampers the DNA repair of cells harboring Gb3Cer/CD77 [6], such as the cancer Raji cells. 
Figure 4. Raji cell viability after treatment with mafosfamide in combination with Stx1 
(0.05 pM) or 3AB (5 mM). Representative experiments performed with Raji cells (A, B) or 
with HL-60 cells (C) as negative control. Cells were treated, as described in the panels of 
Figure 3. At the end of post-incubation, cell survival was assessed with a trypan blue 
permeation assay, as described in Experimental section. The SD values (n = 3) of single 
points are indicated. * p < 0.05 as compared to cells exposed to mafosfamide alone (t-test); 
(D) The curves were obtained by plotting the mean percent of live Raji cells obtained from 
three independent experiments with Stx1 against the logarithm of mafosfamide 
concentrations. The SD values of single points are indicated. 
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Figure 4. Cont. 
 
Conversely, it is well known that CD34+ human progenitor cells lacking the specific toxin receptor 
are spared [10]. The same occurred with HL-60 cells, which do not express Gb3Cer/CD77 and are 
sensitive to the toxic effect induced by mafosfamide, but not by Stx1. Indeed, the combined treatment 
did not potentiate the activity of mafosfamide on these cells (Figure 4C). In contrast, as shown in 
Figure 4D, the significantly different elevations (p < 0.05) of the straight lines obtained by plotting the 
mean percentage of live Raji cells from three independent experiments against the logarithm of drug 
concentrations after treatment with mafosfamide (r = −0.998) or mafosfamide/Stx1 (r = −0.982) 
confirm the Stx1-induced potentiating effect on mafosfamide acting on Raji cells.  
To investigate more closely the mechanism of cell death in treated Raji cells, double staining with 
propidium iodide (PI), as a probe for membrane damage and annexin V, as a probe for apoptosis, was 
performed after 48 h incubation. The annexin V assay is based on flow cytometric detection of  
FITC-conjugated annexin V bound to phosphatidylserine exposed on the outer leaflet of the  
plasma-membrane lipid bilayer of apoptotic cells. Annexin V-positive cells were classified as early 
apoptotic cells (Figure 5, quadrant C4), and annexin V- and PI-double-positive cells were considered 
to be late-apoptotic cells (Figure 5, quadrant C2). The results depicted in the representative cytograms 
in Figure 5 show that treatment of Raji cells with a low concentration of mafosfamide (1 μg/mL) 
induced only a modest significant increase (p < 0.005, t-test) in the number of early ((0.050 ± 0.001) × 106) 
and late apoptotic cells ((0.026 ± 0.001) × 106) with respect to controls ((0.031 ± 0.001) × 106 and 
(0.006 ± 0.001) × 106, respectively), confirming that the alkylating agent in this condition acted mainly 
on cell proliferation (Figure 4). The same occurred with Stx1 (0.05 pM), which slightly changed the 
number of early ((0.043 ± 0.003) × 106; p < 0.05, t-test) and late apoptotic cells ((0.030 ± 0.001) × 106; 
p < 0.005, t-test) with respect to controls (see above) when the toxin was administered alone  
(Figure 5). By contrast, the combined treatment of Raji cells with an inhibitor of DNA repair (Stx1) 
and an alkylating agent (mafosfamide) significantly (p < 0.005, two-way ANOVA) increased the 
number of early ((0.163 ± 0.024) × 106) and late apoptotic cells ((0.120 ± 0.017) × 106) with respect to 
single treatments (see above). There was also a corresponding reduction in live cells (quadrant C3) in 
mafosfamide/Stx1 treated cells. Necrosis (PI positive cells; quadrant C1) was almost absent under 
these conditions. Thus, the combined mafosfamide/Stx1 treatment triggers apoptosis in cancer cells. 
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Figure 5. Determination of apoptosis in Raji cells after treatment with mafosfamide in 
combination with Stx1. Raji cells were treated as described in the upper panel of Figure 3. 
At the end of post-incubation, the cells were analyzed by flow cytometry after staining 
with annexin V and PI. Quadrant C1, necrosis; quadrant C2, late apoptotic cells; quadrant 
C3, live cells; and quadrant C4, early apoptotic cells. Mafosfamide and Stx1 were 1 μg/mL 
and 0.05 pM, respectively. 
 
To gain information on the reproductive integrity of Raji cells after the treatments outlined above, 
the clonogenic assay was performed. Cells scored as survivors were able to produce a colony of at 
least 50 cells within 10 days, indicating that they would give rise to viable offspring in an intact tissue. 
Raji cells were treated with mafosfamide (5–100 μg/mL) or with Stx1 (0.005–0.05 pM) under the 
experimental conditions shown in Figure 3. The clonogenic assay was then carried out by seeding 500 
cells in 24-multiwell culture plates. The clonal efficiency of control Raji cells was 45.9% ± 6.5%  
(n = 4). In these conditions, both mafosfamide (Effective dose 50, ED50 = 11.5 ± 2.1 μg/mL;  
r = −0.979) and Stx1 (Effective concentration EC50 = 0.010 ± 0.001 pM, r = −0.995) assayed at 
different concentrations inhibited the formation of colonies.  
Table 1. Stx1 improves the inhibitory effect of mafosfamide on colony formation by Raji cells. 
 Mafosfamide (μg/mL) DRI a CI b 
None Stx1 (0.05 pM) 
ED85 c 23 15 1.53 0.91 
ED90 29 17 1.70 0.95 
ED98 70 45 1.55 0.74 
a DRI, dose reduction index, calculated by Calculsyn version 2.1; b CI, combination index, calculated by 
Calculsyn version 2.1; c ED, effective dose, calculated by Calculsyn version 2.1. 
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Table 1 shows the ED85, ED90 and ED98 of mafosfamide in the absence and in the presence of 
0.05 pM Stx1 (Calculsyn, version 2.1). The corresponding combination index (CI) and the dose 
reduction index (DRI) were calculated (Calculsyn, version 2.1). CI measures the degree of drug 
interaction in terms of additive effect (CI = 1) or synergistic effect (CI < 1). Under our experimental 
conditions, we consistently obtained CI values below unity indicating a synergistic cooperation 
between mafosfamide and Stx1. The results also showed that the dose of mafosfamide at any given 
effect was lower in the presence of the bacterial toxin (Table 1).  
3. Discussion 
In the present study, we demonstrate for the first time that a quasi-non-toxic concentration of the 
bacterial toxin Stx1 potentiates the cytotoxic action of mafosfamide on Raji cells in a synergistic 
manner. Mafosfamide is a derivative of cyclophosphamide, which, unlike the latter, does not require 
metabolic activation to exert its antitumor activity [12]. Mafosfamide is widely used in the treatment of 
various hematological tumors and is also able to eliminate cancer cells before autologous bone marrow 
transplantation [18]. The DNA damaging activity of mafosfamide is recognized to play a prominent 
and causative role in its cytotoxic and anticancer activity [19]. Mafosfamide induces a variety of 
lesions to nuclear DNA, ranging from interstrand crosslinks, alkylative damages to DNA bases, DNA 
single and double strand breaks (SSBs and DSBs, respectively) [20]. Accordingly, we found that 
exposure of Raji cells or HL-60 cells to mafosfamide results in significant nuclear DNA damage. 
These lesions are scored by FHA as DNA SSBs, which are likely to reflect the majority of the lesions 
caused by the drug. Indeed, SSBs are directly detected, DSBs (due to the denaturing pH of FHA) are 
scored as SSBs, while base damages and interstrand crosslinks are elaborated and converted by repair 
enzymes into SSBs and then detected in this form by FHA [21]. Once produced, the DNA repair 
machinery of Raji cells or HL-60 cells is capable of removing most of mafosfamide lesions to DNA 
within a 4–6 h post-challenge incubation in drug-free medium. Interestingly, repair of the same lesions 
was greatly inhibited when Gb3Cer/CD77-expressing cells (Raji cells) had been pre-conditioned with 
sub-DNA damaging concentrations of Stx1, whereas the rate of DNA repair was unaffected in cells 
that do not harbor the specific toxin receptor (HL-60 cells). This finding is consistent with previous 
studies from our group showing that Stx1 inhibited the resealing of the DNA lesions caused by the 
oxidative agent H2O2 and by the alkylating agent methyl methane sulfonate in cultured sensitive cells, 
such as human endothelial cells [6]. We also found that the sensitivity of endothelial cells to methyl 
methane sulfonate was significantly increased by pre-treatment with Stx1 (unpublished observation). 
Indeed, inhibition of the repair of toxicologically relevant DNA lesions, such as those caused by 
antitumor agents, is known to potentiate their cytotoxicity and is considered as a valuable strategy to 
increase their therapeutic efficacy [22]. Interestingly, inhibition of DNA repair sensitizes various 
tumor cells to the cytotoxic activity of a wide number of alkylating agents, including either 
mafosfamide or its parental analogue cyclophosphamide [22–25]. Accordingly, preconditioning of Raji 
cells with a quasi-non-toxic dose of Stx1 significantly sensitized these cells to the action of 
mafosfamide, as assayed with the trypan blue exclusion assay. Using the more sensitive clonogenic 
assay, we found that Stx1 significantly decreased the ED85, ED90 and ED98 values of mafosfamide 
and; more interestingly, analysis of these data with Calculsyn software revealed that the interaction 
between the two agents was synergistic. This notion is further supported by the observation that, while 
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mafosfamide at the lowest concentration tested (1 μg/mL) is basically cytostatic to Raji cells  
(Figure 4), it becomes cytotoxic toward Stx-primed cells, inducing significant apoptotic cell death. It is 
worth noting that the concentrations of Stx1 (0.05–0.1 pM) used throughout these experiments were 
very low (45–90 toxin molecules/cell). At such doses, it is not cytotoxic and only slightly inhibitory to 
protein synthesis. In other words, Stx1 synergistically interacts with mafosfamide at concentrations 
lower than those previously selected for ex vivo bone marrow purging [26], which, unfortunately, are 
regarded as unsafe for clinical purposes.  
The synergistic cooperation between the two agents is likely to depend on the Stx1-mediated 
inhibition of the DNA repair efficiency of mafosfamide-injured cells. Indeed, we also show that in the 
presence of 3AB, selected as a reference DNA repair inhibitor acting on PARP, the rejoining of 
mafosfamide-induced DNA lesions in Raji cells was impaired to an extent similar to that caused by 
Stx1. This response was also associated with an increase in the sensitivity of Raji cells to mafosfamide 
toxicity. Thus, it is likely that the persistence of unrepaired mafosfamide-induced DNA breaks is 
causally linked to the increased susceptibility of Raji cells to the alkylating agent. Although the precise 
mechanism(s) whereby Stx1 impairs DNA repair machinery was not extensively investigated and is 
beyond the scope of the present study, we hypothesized that it might involve the inhibition of  
PARP-dependent processes [6]. Indeed, it has been shown that ricin, the plant toxin homologous to 
Stx1, catalyzes the release of adenines from poly(ADP-ribosyl)ated PARP in vitro [27]; it is worth 
noting that an extensive depurination might promote precocious degradation of poly(ADP-ribose) 
polymers [27]. Since the effects of PARP directly depend on the extent of poly(ADP-ribosyl)ation, a 
post-translational modification of proteins involving synthesis of ADP-ribose polymers on target 
proteins, it is reasonable to hypothesize that ricin and related toxins might accelerate in vivo 
deadenylation of either automodified PARP or of specific acceptor poly(ADP-ribosyl)ated proteins. 
This would, in turn, disrupt PARP-dependent nuclear processes, including DNA repair. The hypothesis 
that Stx1 may act via a PARP-dependent mechanism is indirectly supported by the following 
observations: (i) 3AB promotes effects quantitatively similar to those caused by Stx1 and (ii) the 
cooperative action of DNA repair enzymes involved in alkylative damage repair depends on the extent 
of poly(ADP-ribosyl)ation [6,28]. 
Purging of cancer cells from bone marrow before transplantation is a widely used and effective 
strategy in the treatment of lymphomas and leukemias [18]. Stx1 targets cells that express the 
glycolipid Gb3Cer/CD77, whose frequent occurrence on tumor cells derived from patients with 
hematological cancers (follicular lymphoma, multiple myeloma, chronic lymphocytic leukemia), along 
with its absence on human CD34+ hematopoietic stem cells, justify the ex vivo use of cytotoxic 
concentrations of Stx1 in purging CD77+ tumor cells from autologous stem cell transplants [10,29]. 
However, the fact that Gb3Cer/CD77 is expressed also by many other cell types in the body, combined 
with the very high intrinsic toxicity of Stx1 [1,13,14], discourages the use of the toxin even in such an 
ex vivo setting, unless quasi-non-toxic concentrations of Stx1 are used in combination with an 
anticancer drug, as suggested in the present paper. 
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4. Experimental Section 
4.1. Drugs 
The Stx1-producer E. coli C600 (H19J) was kindly supplied by Dr Alison O’Brien (Department of 
Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, 
MD, USA). Stx1 was purified by receptor analogue affinity chromatography [30] on  
globotriose—Fractogel (IsoSep AB, Lund, Sweden). The purity of the toxin was verified by  
SDS-polyacrylamide gel electrophoresis. Toxicity was assayed by measuring the inhibition of 
translation (IC50 = 0.9 pM) in human umbilical vein endothelial cells treated with the toxin, as 
previously described [4]. Mafosfamide was kindly provided by Prof. Vittorio Rizzoli (Sezione di 
Ematologia e Centro Trapianti Midollo Osseo, Università di Parma, Parma, Italy). 
4.2. Culture of Cells 
Raji cells, a cell line presenting genomic stability [31] even though derived more than 45 years ago 
from a patient with Burkitt lymphoma [32], were kindly provided by Prof. Andrea Bolognesi 
(Dipartimento di Patologia Sperimentale, Università di Bologna, Bologna, Italy). HL-60 cells, a 
generous gift of Prof. Carmela Fimognari (Dipartimento di Farmacia, Università di Bologna, Bologna, 
Italy), were purchased by Istituto Zooprofilattico (Brescia, Italy). Cells were maintained in RPMI 1640 
medium (Lonza, Walkersville, MD, USA) containing antibiotics (60 U/mL penicillin, 60 μg/mL 
streptomycin, Cambrex, Walkersville, MD, USA) and supplemented with 4 mM L-glutamine (Sigma 
Aldrich, St. Louis, MO, USA) and 10% or 20% fetal bovine serum (Lonza, Walkersville, MD, USA), 
with Raji cells or HL-60 cells, respectively. In the following experiments, Raji cells or HL-60 cells  
(1 × 106) were seeded in 1.5 mL complete growth medium in 3.5 cm diameter dishes, incubated 
overnight and then treated, as described in Figures and their legends. Cultures were kept in an 
incubator at 37 °C in a water-saturated 5% CO2 atmosphere in air. 
4.3. Protein Synthesis Measurement in Whole Cells 
Cells were treated, as indicated in the legends to Figures 1 and 2 and in the panel of Figure 2. At the 
end of the incubation period, protein synthesis was measured as the rate of incorporation of 
radiolabeled leucine during a 30 min incubation of the cells at 37 °C in 1.5 mL of complete medium 
containing 2 μCi of [3H]leucine (62 Ci/mmol; Amersham Biosciences, Bucks, UK). The cells were 
centrifuged 5 min at 200 × g and washed three times with 0.5 mL of ice-cold phosphate buffered saline 
(PBS) containing 10 mM leucine. The cellular pellets were treated with 0.5 mL of ice-cold 10% (v/v) 
trichloroacetic acid, followed by 5 min of incubation on ice and centrifugation for 10 min at  
13,000 × g. The procedure was repeated three times. Finally, the precipitated cellular proteins were 
resuspended in 200 μL of 0.2 M KOH, and the radioactivity was measured in a liquid scintillation 
counter. In each experiment, blank values obtained by incubating the cells in the presence of 
radiolabeled leucine (see above) for 30 min at 0 °C were subtracted.  
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4.4. Fast Halo Assay  
DNA damage and repair were analyzed with the FHA, conducted as previously described [17,21]. 
Briefly, after the treatments, the cells were resuspended at 4.0 × 104/mL in ice-cold PBS containing  
5 mM EDTA; 25 μL of this cell suspension were diluted with an equal volume of 2% low melting 
agarose in PBS and immediately sandwiched between an agarose-coated slide and a coverslip. The 
latter were removed, and the slides were immersed in 300 mM NaOH for 15 min at room temperature. 
Ethidium bromide (10 μg/mL) was directly added to NaOH during the last 5 min of incubation. The 
ethidium bromide-labeled DNA was visualized using a Leica DMLB/DFC300F fluorescence 
microscope (Leica Microsystems, Wetzlar, Germany) equipped with an Olympus Colorview IIIU CCD 
camera (Olympus Italia Srl, Segrate, Italy), and the resulting images were digitally recorded on a PC 
and processed with image analysis software (Scion Image, Scion Corporation, Frederick, MD, USA). 
The amount of fragmented DNA diffusing out of the nuclear cage, i.e., the extent of strand scission, 
was quantified by calculating the nuclear spreading factor, which represents the ratio between the total 
area (halo and nucleus) and that of the nucleus. Data are expressed as RNSF, calculated by subtracting 
the nuclear diffusion factor of control cells from those of treated cells.  
4.5. Determination of Cell Survival and Apoptosis 
Cell proliferation and viability were determined by counting the cells after proper dilution; cell 
death was monitored by counting cells permeated by 0.06% trypan blue. Apoptosis was evaluated by 
assessing the annexin V binding to phosphatidylserine exposed on the outer leaflet of the plasma 
membrane of apoptotic cells and by evaluating, simultaneously, the exclusion of PI (ApoScreen 
Annexin V apoptosis kit-FITC; Beckman Coulter, Miami, FL, USA) by flow cytometry. 
4.6. Clonogenic Assay 
The effect of exposure of Raji cells to Stx1 and mafosfamide, either alone or in combination, was 
evaluated by a clonogenic assay. Cells were incubated with Stx1 and mafosfamide, according to the 
experimental set described in Figure 3 (left upper panel). After the washing procedures, 500  
colony-forming Raji cells were cultured in 500 μL Iscove’s modified Dulbecco’s medium containing 
1.4% methylcellulose, 25% fetal bovine serum, 2% bovine serum albumin, 2 mM L-glutamine and  
50 μM 2-mercaptoethanol (Human methylcellulose base media; R&D Systems Inc., Minneapolis, MN, 
USA). Cultures were incubated at 37 °C in humidified atmosphere containing 5% CO2 for 10 days. 
Colonies of more than 50 cells were scored visually under a microscope by three independent 
observers. Each experimental point was performed in duplicate and the experiments were repeated  
four times.  
4.7. Statistics 
Differences in continuous variables were compared with t-tests or with two-way ANOVA after 
verifying the normality of their distribution. A value of p < 0.05 was considered statistically 
significant. Correlation between variables was assessed by the Pearson correlation coefficient. 
Differences in slopes and elevations of different straight lines were tested by linear regression. 
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5. Conclusions 
A strategy based on the combination of a DNA repair inhibitor and an anticancer agent has been 
exploited to ameliorate the clinical outcomes of antitumor therapies [22]. In particular, PARP 
inhibitors have gained recent attention, since they augment head and neck cancer cell susceptibility to 
cetuximab in vitro [33]. This therapeutic agent targets the epidermal growth factor receptor; thus, the 
combined treatment seems feasible in different human tumors with aberrant epidermal growth factor 
receptor signaling. In this respect, our findings pose a rationale for the evaluation and possible 
utilization of an approach involving association between mafosfamide and Stx1, in a specific, but 
clinically relevant, situation; namely, selective purging of Gb3Cer/CD77+ tumor cells before 
autologous bone marrow transplantation. 
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